Global Thematic Partners LLC trimmed its stake in Teladoc Health Inc (NYSE:TDOC) by 44.1% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 232,192 shares of the health services provider’s stock after selling 183,243 shares during the period. Global Thematic Partners LLC’s holdings in Teladoc Health were worth $19,439,000 as of its most recent SEC filing.

Several other large investors also recently bought and sold shares of the company. CNB Bank grew its position in Teladoc Health by 100.0% during the third quarter. CNB Bank now owns 400 shares of the health services provider’s stock worth $27,000 after buying an additional 200 shares in the last quarter. Capital Investment Advisory Services LLC lifted its position in shares of Teladoc Health by 800.0% in the 3rd quarter. Capital Investment Advisory Services LLC now owns 450 shares of the health services provider’s stock worth $30,000 after acquiring an additional 400 shares during the period. Marshall Wace North America L.P. acquired a new stake in shares of Teladoc Health during the 1st quarter worth approximately $35,000. Quadrant Capital Group LLC grew its holdings in shares of Teladoc Health by 32.4% during the 3rd quarter. Quadrant Capital Group LLC now owns 621 shares of the health services provider’s stock worth $41,000 after purchasing an additional 152 shares in the last quarter. Finally, American National Bank acquired a new stake in shares of Teladoc Health during the 3rd quarter worth approximately $54,000.

A number of brokerages recently commented on TDOC. Bank of America lowered Teladoc Health from a “buy” rating to a “neutral” rating and upped their target price for the company from $82.00 to $90.00 in a research note on Thursday, January 9th. SunTrust Banks reissued a “hold” rating and issued a $80.00 price target on shares of Teladoc Health in a research report on Monday, December 2nd. Jefferies Financial Group cut shares of Teladoc Health from a “buy” rating to a “hold” rating and set a $80.00 price target for the company. in a research note on Friday, December 6th. JPMorgan Chase & Co. lifted their price objective on Teladoc Health from $94.00 to $112.00 and gave the company an “overweight” rating in a report on Tuesday. Finally, Stifel Nicolaus started coverage on Teladoc Health in a research note on Monday, November 25th. They issued a “hold” rating and a $83.00 price objective on the stock. Nine research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the stock. The stock has an average rating of “Buy” and a consensus target price of $91.00.

NYSE:TDOC traded up $2.65 on Tuesday, reaching $98.25. The stock had a trading volume of 1,809,244 shares, compared to its average volume of 1,447,840. The company has a quick ratio of 6.55, a current ratio of 6.55 and a debt-to-equity ratio of 0.44. The company has a market capitalization of $6.92 billion, a P/E ratio of -66.84 and a beta of 1.38. Teladoc Health Inc has a 1-year low of $48.57 and a 1-year high of $101.28. The stock has a fifty day moving average price of $83.83 and a 200-day moving average price of $72.98.

Teladoc Health (NYSE:TDOC) last posted its quarterly earnings data on Wednesday, October 30th. The health services provider reported ($0.28) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.40) by $0.12. Teladoc Health had a negative net margin of 20.15% and a negative return on equity of 11.23%. The company had revenue of $137.96 million during the quarter, compared to analyst estimates of $136.46 million. During the same quarter last year, the business posted ($0.34) earnings per share. The company’s revenue was up 24.3% on a year-over-year basis. Sell-side analysts predict that Teladoc Health Inc will post -1.55 earnings per share for the current fiscal year.

In other news, CAO Gabriel R. Cappucci sold 9,569 shares of the firm’s stock in a transaction on Thursday, October 31st. The stock was sold at an average price of $75.00, for a total value of $717,675.00. Following the completion of the sale, the chief accounting officer now directly owns 10,798 shares in the company, valued at $809,850. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Adam C. Vandervoort sold 50,955 shares of the firm’s stock in a transaction on Thursday, October 31st. The shares were sold at an average price of $75.00, for a total value of $3,821,625.00. Following the completion of the sale, the insider now owns 9,769 shares of the company’s stock, valued at $732,675. The disclosure for this sale can be found here. Insiders sold a total of 68,099 shares of company stock worth $5,151,311 over the last three months. 3.14% of the stock is owned by company insiders.

Teladoc Health Profile

Teladoc Health, Inc provides telehealth services. It offers a portfolio of services and solutions covering 450 medical subspecialties, such as flu and upper respiratory infections, cancer, and congestive heart failure. The company provides its services through mobile devices, the Internet, video, and phone.

See Also: Investing in Dividend Stocks

Want to see what other hedge funds are holding TDOC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Teladoc Health Inc (NYSE:TDOC).

Institutional Ownership by Quarter for Teladoc Health (NYSE:TDOC)

Receive News & Ratings for Teladoc Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teladoc Health and related companies with MarketBeat.com's FREE daily email newsletter.